Learning and using multiple languages: Experiences of adults with ADHD

Living with symptoms of Attention Deficit-Hyperactivity Disorder (ADHD) in adulthood: a systematic review protocol of qualitative evidence

This study investigated the beliefs about additional language learning and use and knowledge of additional languages of 226 multilingual adults with Attention-deficit/hyperactivity disorder (ADHD) with Polish L1. The data were collected via an online questionnaire with Likert-type statements. Data were analyzed using mixed models (GLMMs). The findings show that a) individuals with ADHD hold a neutral view of their additional language learning and use experiences; b) the hyperactivity/impulsivity ADHD presentation may positively affect additional language learning; and c) Autism spectrum disorder (ASD) or dyslexia has no impact on additional language knowledge in the context of ADHD. The discussion points to the importance of attention in additional language acquisition and the possible compensatory role of ADHD and ASD in the context of dyslexia and language learning.

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that begins in childhood and often persists into adulthood. ADHD increases the risk of various negative impacts, and pharmacists are well positioned to address these issues in the community. This survey study aims to first identify pharmacists' ADHD knowledge gaps and experience with ADHD management and to second assess their preferences for continuing education and their experience with sleep-related issues in ADHD. A survey was sent to Part A Ontario pharmacists with active licenses who opted in to receive research-related emails (n = 6022). Descriptive statistics were used to analyze survey data, while free-form answers were pooled and evaluated for common themes and trends. A total of 238 complete responses were received. The average self-reported ADHD knowledge was 5.8 ± 1.96 on a 10-point scale. There was no correlation between the number of years of practice as a pharmacist, the number of working hours per week or the location of practice on pharmacists' self-reported knowledge scores. There was a significant difference in self-reported knowledge of ADHD between pharmacists who were not aware of the Canadian ADHD Resource Alliance (CADDRA) guidelines (5.1 ± 2.1) and those who refer to it for standard of care (7.1 ± 1.5). Almost all pharmacists (95%) indicated they could benefit from additional ADHD education, with a strong preference for "online continuing education modules" (81%). The majority of responders considered psychostimulant ADHD medication as the major possible contributor to sleep disturbances (47%) in ADHD, highlighting a need for further education on the inconclusive link between ADHD medication effects on sleep. The study results raise the concern that pharmacists may require additional ADHD education but also show the lack of awareness of available resources, such as the CADDRA guidelines. Can Pharm J (Ott) 2021;154:xx-xx.

BackgroundThere is limited evidence of the unmet needs and experiences of adults with Attention Deficit Hyperactivity Disorder (ADHD) in the published scientific literature. This study aimed to explore the experiences of adults in England with ADHD regarding access to diagnostic and treatment services, ADHD-related impairment and to compare experiences between patients diagnosed during adulthood and childhood.MethodsIn this qualitative study, 30 adults with ADHD were recruited through an ADHD charity (n = 17) and two hospital outpatient clinics for adults with ADHD in England (n = 13). Half of the participants were diagnosed with ADHD during childhood or adolescence and the remainder during adulthood. Semi-structured interviews were conducted and data was analysed using a thematic approach based on Grounded Theory principles.ResultsAnalysis revealed five core themes: ‘An uphill struggle’: the challenge of accessing services, ‘Accumulated Psychosocial Burden and the Impact of ADHD’, ‘Weighing up Costs vs. Benefits of ADHD Pharmacological Treatment’, ‘Value of Non-pharmacological Treatment’ and ‘Barriers to Treatment Adherence’. Accessing services and the challenges associated with securing a definitive diagnosis of ADHD in adulthood was an ‘uphill struggle’, often due to sceptical and negative attitudes towards ADHD by healthcare professionals. ADHD-related impairment had an overwhelmingly chaotic impact on every aspect of patients’ lives and many felt ill equipped to cope. A persistent sense of failure and missed potential from living with the impact of ADHD impairment had led to an accumulated psychosocial burden, especially among those diagnosed from late adolescence onwards. In contrast, positive adjustment was facilitated by a younger age at diagnosis. Although medication was perceived as necessary in alleviating impairment, many felt strongly that by itself, it was inadequate. Additional support in the form of psychological therapies or psycho-education was strongly desired. However, few patients had access to non-pharmacological treatment. In some, medication use was often inadequately monitored with little or no follow-up by healthcare professionals, leading to poor adherence and a sense of abandonment from the healthcare system.ConclusionThe findings suggest that the unmet needs of adults with ADHD are substantial and that there is a wide gap between policy and current practice in England.

Metacognitive knowledge of attention in children with and without ADHD symptoms

Individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely than those without ADHD to initiate smoking and develop nicotine dependence. Recent research indicates that adults with ADHD experience more severe nicotine withdrawal symptoms than those without ADHD. However, little is known about nicotine withdrawal in adolescent smokers with history of ADHD. Among a sample of 134 nicotine-dependent adolescents entering a smoking cessation research study, participants completed the Minnesota Nicotine Withdrawal Scale (MNWS) and lifetime diagnostic assessment for ADHD during the baseline visit. Responses on individual items and MNWS total score were compared between participants with and without history of ADHD. In addition, correlations between MNWS responses and current ADHD symptoms were investigated among participants with history of ADHD. Forty-eight participants (36%) met lifetime ADHD criteria. Adolescent smokers with history of ADHD scored significantly higher on MNWS than those without history of ADHD. Among participants with history of ADHD, responses on the MNWS difficulty concentrating, restlessness/impatience, and anxiety/nervousness items each correlated positively with several current ADHD symptoms. Treatment-seeking adolescent smokers with history of ADHD are more likely to endorse nicotine withdrawal symptoms than those without history of ADHD. However, it does not appear that the symptoms reported in this sample represent a valid "withdrawal syndrome," particularly because these smokers had not yet formally attempted to quit. Rather, the data likely reflect common features between ADHD and nicotine withdrawal. Smoking research, particularly among adolescents in whom ADHD is so common, should carefully consider the complex issue of comorbid ADHD and nicotine dependence.

Bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD) may copresent and manifest as complex clinical presentations, often accompanied by further comorbidities such as anxiety and substance use disorders. ADHD/BD comorbidity not only relies on a widely reported symptomatological and neurobiological overlap, but it also creates an intricate interplay between ADHD, affective and other psychiatric conditions, requiring a more nuanced understanding of their comorbid nature. Moreover, clinical and nosological perspectives on the nature of the ADHD/BD comorbidity may significantly vary across developmental stages, ranging from an overestimated comorbidity (possibly due to the confound role of greater symptoms' overlap in childhood, adolescence and youth cases) to a prodromal developmental pattern (i.e., from ADHD to BD) or a separate nosological entity (“ADHD-BD”).1 In younger patients, in particular, recent literature also suggests a possible specific role of emotional dysregulation, a common key feature of ADHD and bipolar spectrum disorders, acting as a confound variable that may enhance the misconception of ADHD/BD comorbidity and favor the misdiagnosis of ADHD as a BD spectrum disorder.2 Clearly, the emphasis on the need to disentangle the complex relationship between juvenile ADHD and BD highlights the challenges in delineating these disorders for better diagnostic characterization and therapeutic indications. The systematic review by Miskowiak et al.3 addresses a highly relevant clinical topic, reporting on the available evidence on the efficacy and safety of ADHD pharmacotherapies to treat cognitive impairment and ADHD symptoms in juvenile and adult BD. Shared neurobiological dysregulations, particularly involving dopamine and norepinephrine signalling pathways, may significantly contribute to the symptomatic overlap between BD and ADHD. However, pharmacological interventions targeting dopamine and noradrenaline pathways (such as stimulants and alpha-2-adrenergic agonists) long held promise to ameliorate cognitive deficits and ADHD symptoms in individuals with BD. Indeed, the evidence relative to dysfunctions of the dopamine transporter (DAT) gene and catechol-O-methyltransferase (COMT) gene variants underscores the intricate interplay between these disorders and prompts for therapeutic implications.4 Miskowiak et al.3 also report preliminary favorable evidence of efficacy of ADHD drugs in treating ADHD symptoms in BD, with a current lack of evidence for psychostimulants to trigger or exacerbate mania and insufficient evidence to conclude on their role in improving cognitive symptoms in BD. Also in our previous work,5 we underscored the potential benefits of adjunctive therapy in alleviating ADHD symptoms in BD patients. Indeed, while mood stabilization should remain the main target of BD patients (as impulsivity, hyperactivity, and inattention symptoms may recede after stabilization), the presence of “residual” (and particularly cognitive) symptoms may require specific ADHD drugs. We agree that methylphenidate and mixed amphetamine salts represent the most promising options in the treatment of BD, with robust beneficial effects observed particularly in pediatric and adolescent populations. However, the paucity of data concerning atomoxetine, viloxizine, modafinil, armodafinil, and lisdexamfetamine (that, importantly, is the only stimulant marketed for use in ADHD to be studied as an add-on strategy for treatment-resistant bipolar depression) demands for a still cautious and highly individualized approach. On the other hand, we also highlighted a favorable safety profile of ADHD medications with no increased risk of manic episodes, especially when administered alongside mood stabilizers, and this evidence should favor their use in BD. A more recent examination of comorbidities in youth with BD explored both clinical characteristics and pharmacological treatment approaches.6 This review underscores the relevance of customized interventions to effectively address the diverse needs of this patient cohort. However, it also highlights a notable gap in research concerning pharmacological interventions for BD and its concurrent conditions, particularly in the pediatric and adolescent age groups. Despite the promising efficacy and safety profile of ADHD medications, significant gaps remain in our understanding of their cognitive effects and long-term outcomes in BD patients. Future research endeavors should prioritize comprehensive cognitive assessments, individual characterization of patients and larger sample sizes to elucidate the potential cognitive benefits of these medications. Also, specific attention should be devoted to develop controlled clinical trials sensitive to emotional dysregulation along different developmental stages, in order to really improve the prognosis of these highly complex patients, that require finely characterized diagnostic processes and highly personalized therapies. Indeed, tailored interventions addressing comorbidities and developmental nuances are imperative to optimize treatment outcomes and enhance the quality of life for individuals with BD and ADHD features. In conclusion, a multifaceted approach encompassing neurobiological insights, clinical complexity, and treatment implications is essential in navigating at the intersection of ADHD medications and BD. By integrating findings from different clinical perspectives, we can advance personalized care paradigms, tailored to the unique needs of individuals within the BD spectrum. Embracing interdisciplinary collaboration and prioritizing specific research endeavors are crucial steps toward optimizing treatment outcomes and improving the quality of life for this complex patient population. The author declares no conflicts of interest. Data sharing not applicable – no new data generated.

Attention deficit–hyperactivity disorder (ADHD) comprises a common and highly heritable group of syndromes with childhood onset that are characterised by impairments in attention span, impulse control and/or activity level. Neurobehavioral, imaging, treatment and genetic studies are consistent with the clinical symptoms of ADHD being caused by abnormalities of the ventral projections of catecholamine pathways in the brain. Twin and adoption studies suggest that there is a strong genetic influence on ADHD with a heritability of approximately 0.76. Linkage studies have identified chromosome areas 5p13, 11q22–25, 17p11 and bin16.4 as being associated with ADHD. Candidate gene studies have focused on the genes influencing catecholaminergic and serotoninergic pathways. Whilst no one gene has yet been unequivocally demonstrated to be causally associated with ADHD, systematic review and meta‐analysis supports the involvement of several genes (DRD4 and DRD5, DAT1, SNAP25 and the 5‐HTT gene). Genome wide association scans have not yet found any genome‐wide significant associations. Preliminary findings suggest increased numbers of copy number variants (CNVs) in ADHD. Key Concepts: ADHD is characterised by pervasive and impairing inattention, impulsivity and hyperactivity. ADHD is a neurodevelopmental disorder with a prevalence of approximately 5% worldwide. ADHD is thought to be associated with abnormalities in dopaminergic and noradrenergic functioning. Twin and adoption studies have established that ADHD is highly heritable with a heritability of approximately 0.76. Linkage studies have identified chromosome areas 5p13, 11q22–25, 17p11 and bin16.4 as being associated with ADHD. Candidate gene studies have thus far tended to focus on genes located within the dopaminergic, noradrenergic and serotonergic pathways. Converging lines of evidence and meta analyses of candidate gene studies have identified that polymorphisms within the dopamine receptor genes 4 and 5 (DRD4 and DRD5), the dopamine transporter gene (DAT1), the synaptosome‐associated protein gene (SNAP25) and the serotonin receptor gene (5‐HTT) are associated with an increased the risk of ADHD. None of these genes have yet be unequivocally associated with ADHD as p values do not yet meet the strict criteria required to demonstrate causality (p<10 −8 ). Whilst signals of interest have been identified using GWAS, none have yet reached the required levels of statistical significance. Recent studies have suggested that those with ADHD have increased numbers of CNVs. However, further study is required to investigate the specificity of these findings to ADHD.

Attention deficit hyperactivity disorder (ADHD) is a multifactorial neurodevelopmental disorder, yet the interplay between ADHD polygenic risk scores (PRSs) and other risk factors remains relatively unexplored. The authors investigated associations, confounding, and interactions of ADHD PRS with birth-related, somatic, and psychosocial factors previously associated with ADHD. Participants included a random general population sample (N=21,578) and individuals diagnosed with ADHD (N=13,697) from the genotyped Danish iPSYCH2012 case cohort, born between 1981 and 2005. The authors derived ADHD PRSs and identified 24 factors previously associated with ADHD using national registers. Logistic regression was used to estimate associations of ADHD PRS with each risk factor in the general population. Cox models were used to evaluate confounding of risk factor associations with ADHD diagnosis by ADHD PRS and parental psychiatric history, and interactions between ADHD PRS and each risk factor. ADHD PRS was associated with 12 of 24 risk factors (odds ratio range, 1.03-1.30), namely, small gestational age, infections, traumatic brain injury, and most psychosocial risk factors. Nineteen risk factors were associated with ADHD diagnosis (odds ratio range, 1.20-3.68), and adjusting for ADHD PRS and parental psychiatric history led to only minor attenuations. Only the interaction between ADHD PRS and maternal autoimmune disease survived correction for multiple testing. Higher ADHD PRS in the general population is associated with small increases in risk for certain birth-related and somatic ADHD risk factors, and broadly to psychosocial adversity. Evidence of gene-environment interaction was limited, as was confounding by ADHD PRS and family psychiatric history on ADHD risk factor associations. This suggests that the majority of the investigated ADHD risk factors act largely independently of current ADHD PRS to increase risk of ADHD.

Background/Objectives: Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder frequently associated with other neuropsychiatric conditions, characterized by high clinical heterogeneity and a complex genetic background. Recent studies suggest that copy number variations (CNVs) may contribute to ADHD susceptibility, particularly when involving genes related to brain development, attention regulation, and impulse control. This study investigated the association between CNVs and ADHD phenotype by identifying patients with and without potential pathogenic CNVs. Methods: We evaluated 152 well-characterized ADHD pediatric patients through comprehensive clinical assessments, including dysmorphic features, brain MRI, EEG patterns, and cognitive testing. CNVs were identified using array Comparative Genomic Hybridization (array-CGH). Participants were classified as carrying potentially causative CNVs (PC-CNVs), non-causative CNVs (NC-CNVs), or without CNVs (W-CNVs) and statistically compared across clinical and neurodevelopmental measures. Results: CNVs were identified in 81 participants (53%), comprising 13 with PC-CNVs (8.5%) and 68 with NC-CNVs (44.7%). ADHD symptoms were pronounced across all groups, but PC-CNVs showed a higher burden of comorbidities, suggesting a stronger genetic contribution to ADHD complexity. Significant differences were observed in oppositional behavior, inattentive symptoms, brain MRI findings, and developmental language anomalies. Several CNVs involved genes previously implicated in neurodevelopmental disorders, supporting a potential genetic contribution to the clinical complexity of ADHD. Conclusions: This exploratory study supports the role of CNVs in ADHD susceptibility and highlights the value of genetic screening for understanding clinical variability. Larger studies are needed to clarify genotype–phenotype correlations in ADHD and to guide personalized clinical management.

The "Children ADHD Disease Detection Using Pose Estimation Techniques" project seeks to transform the early diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) in children using sophisticated pose estimation algorithms. The novel method scrutinizes children's movement patterns and postures to detect possible symptoms of ADHD, providing a non-invasive and objective alternative to conventional assessment methods. ADHD, a neurodevelopmental condition that affects school performance and social function, stands to gain enormously from early detection and treatment. The project improves the validity and responsiveness of ADHD diagnoses through the use of PoseNet for pose estimation. The system records and analyzes the movement of the body during particular activities that are designed to trigger typical ADHD patterns of behavior. The project uses sensors, cameras, or depth sensors to record detailed movement data such as joint locations, angles, and time information. This information is used as input for a trained Support Vector Machine (SVM) model, which makes predictions about movement patterns of ADHD versus normal development. While this technology is promising, it is meant to augment and not replace thorough clinical evaluation, since ADHD is a complex disorder that needs to be approached in a holistic manner. Ethical issues, specifically around data privacy and the possibility of misuse, also need to be considered. This project is a major step forward in child mental health assessment. By bringing high-tech capabilities to the imperative of early and correct detection of ADHD, it can potentially enhance diagnostic precision, facilitate earlier intervention, and ultimately raise the quality of life in children with ADHD. Extensive testing and verification will be imperative to establish reliability, making this technique an important resource in ADHD assessment and care.

Attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are two highly heritable neurodevelopmental disorders. Several lines of evidence point towards the presence of shared genetic factors underlying ASD and ADHD. We conducted genomic analyses of common risk variants (i.e. single nucleotide polymorphisms, SNPs) shared by ASD and ADHD, and those specific to each disorder. With the summary data from two GWAS, one on ASD (N=46,350) and another on ADHD (N=55,374) individuals, we used genomic structural equationmodelling and colocalization analysis to identify SNPs shared by ASD and ADHD and SNPs specific to each disorder. Functional genomic analyses were then conducted on shared and specific common genetic variants. Finally, we performed a bidirectional Mendelian randomization analysis to test whether the shared genetic risk between ASD and ADHD was interpretable in terms of reciprocal relationships between ASD and ADHD. We found that 37.5% of the SNPs associated with ASD (at p<1e-6) colocalized with ADHD SNPs and that 19.6% of the SNPs associated with ADHD colocalized with ASD SNPs. We identified genes mapped to SNPs that are specific to ASD or ADHD and that are shared by ASD and ADHD, including two novel genes INSM1 and PAX1. Our bidirectional Mendelian randomization analyses indicated that the risk of ASD was associated with an increased risk of ADHD and vice versa. Using multivariate genomic analyses, the present study uncovers shared and specific genetic variants associated with ASD and ADHD. Further functional investigation of genes mapped to those shared variants may help identify pathophysiological pathways and new targets for treatment.

BackgroundIn response to COVID-19, there has been increasing momentum in telehealth development and delivery. To assess the anticipated exponential growth in telehealth, it is important to accurately capture how telehealth has been used in specific mental health fields prior to the pandemic.ObjectiveThis systematic review aimed to highlight how telehealth has been used with clinical samples in the neurodevelopmental field, including patients with neurodevelopmental disorders (NDDs), their families, and health care professionals. To identify which technologies show the greatest potential for implementation into health services, we evaluated technologies for effectiveness, economic impact, and readiness for clinical adoption.MethodsA systematic search of literature was undertaken in April 2018 and updated until December 2019, by using the Medline, Web of Science, Scopus, CINAHL Plus, EMBASE, and PsycInfo databases. Extracted data included the type of technology, how the technology was used (ie, assessment, treatment, and monitoring), participant characteristics, reported outcomes and authors’ views on clinical effectiveness, user impact (ie, feasibility and acceptability), economic impact, and readiness for clinic adoption. A quality review of the research was performed in accordance with the Oxford Centre for Evidence-Based Medicine Levels of Evidence.ResultsA total of 42 studies met the inclusion criteria. These studies included participants and family members with autism spectrum disorders (21/42, 50%), attention deficit hyperactivity disorders (8/42, 19%), attention deficit hyperactivity or autism spectrum disorders (3/42, 7%), communication disorders (7/42, 17%), and tic disorders (2/42, 5%). The focus of most studies (33/42, 79%) was on treatment, rather than assessment (4/42, 10%) or monitoring (5/42, 12%). Telehealth services demonstrated promise for being clinically effective, predominantly in relation to diagnosing and monitoring NDDs. In terms of NDD treatment, telehealth services were usually equivalent to control groups. There was some evidence of positive user and economic impacts, including increased service delivery efficiency (eg, increased treatment availability and decreased waiting times). However, these factors were not widely recorded across the studies. Telehealth was demonstrated to be cost-effective in the few studies that considered cost-effectiveness. Study quality varied, as many studies had small sample sizes and inadequate control groups. Of the 42 studies, only 11 (26%) were randomized controlled trials, 12 (29%) were case studies or case series, 6 (14%) were qualitative studies, and 5 (12%) were noncomparative trials.ConclusionsTelehealth has the potential to increase treatment availability, decrease diagnosis waiting times, and aid in NDD monitoring. Further research with more robust and adequately powered study designs that consider cost-effectiveness and increased efficiency is needed. This systematic review highlights the extent of telehealth technology use prior to the COVID-19 pandemic and the movement for investing in remote access to treatments.Trial RegistrationPROSPERO International Prospective Register of Systematic Reviews CRD42018091156; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018091156

BackgroundYoung adolescents’ and their parents’ experiences with Attention-Deficit/Hyperactivity Disorder (ADHD) and its treatment were explored to investigate beliefs and attitudes regarding use of stimulant medication, and their influence on treatment decisions.MethodsUsing in-depth qualitative interviews, 12 adolescents with ADHD aged 12 – 15 years, and their parents described their experiences of ADHD and its treatment. Twenty four interviews, 12 with adolescents and 12 with their parents elicited detailed descriptions of beliefs about ADHD, attitudes about stimulant use and the circumstances surrounding treatment decisions. Verbatim transcripts were iteratively analyzed by a team of researchers following an interpretive interactionist framework.ResultsYoung people offered three themes describing ADHD: 1) personality trait, 2) physical condition or disorder, and 3) minor issue or concern. Regarding medication use, youth described 1) benefits, 2) changes in sense of self, 3) adverse effects, and 4) desire to discontinue use. Parents’ beliefs were more homogeneous than youth beliefs, describing ADHD as a disorder requiring treatment. Most parents noted benefits from stimulant use. Themes were 1) medication as a last resort, 2) allowing the child to reach his or her potential; and 3) concerns about adverse and long-term effects. Families described how responsibility for treatment decisions is transferred from parent to adolescent over time.ConclusionsYoung adolescents can have different beliefs about ADHD and attitudes about medication use from their parents. These beliefs and attitudes influence treatment adherence. Incorporating input from young adolescents when making clinical decisions could potentially improve continuity of treatment for youth with ADHD.

Background and Objectives:Attention deficit hyperactivity disorder (ADHD), while representing the most frequently diagnosed and treated condition in child and adolescent psychiatry, continues to be underrecognized and inadequately managed in adult populations. Numerous studies have explored how ADHD may be connected to the immune system and inflammatory processes. These studies have focused particularly on ADHD, stress, anxiety and immune dysregulation. High Mobility Group Box 1 (HMGB1), a nuclear transcription factor and a late-phase mediator of inflammation, has been found to be elevated in various neuropsychiatric conditions. This study aimed to elucidate the potential contribution of inflammatory mechanisms to the pathophysiology of ADHD by quantifying HMGB1 levels.Materials and Methods:43 ADHD patients and 42 controls with an age between 18–65 years were enrolled. Patients with any acute or chronic psychiatric disease, chronic inflammatory or autoimmune disease, substance addiction, malignancy, severe systemic disease, schizophrenia, mental retardation, a history of surgery or head trauma in the last 6 months and who were on vitamin or fish oil supplements or steroids were excluded. Blood samples were obtained and HMGB1 was measured with Enzyme-Linked Immuno Sorbent Assay method.Results:The two groups exhibited comparable sociodemographic characteristics. HMGB1 levels were significantly higher in ADHD group than controls (967.5 ± 462.0 ng/mL vs 693.4 ± 366.9 ng/mL, p = 0.003).Conclusion:In our study, the finding that HMGB1 serum levels were higher in adult ADHD patients compared to healthy controls supports the hypothesis that chronic low-grade inflammation, which is both driven and detected by HMGB1, may be associated with ADHD through the possibility of causing neurodevelopmental disorders. It is known that HMGB1 is effective in the diagnosis and prognosis of immune system diseases. Therefore, our results show that HMGB1 may be related to the pathophysiology of ADHD.